| gap-pubmed-20260410- | What explains genetic heterogeneity within single families affected by recessive | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do compound heterozygous GDAP1/MMACHC mutations interact to modify disease p | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What genetic factors cause ataxia/neuropathy in families where exome sequencing | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Can causality be established between amyloid levels and tau propagation patterns | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does amyloid mechanistically facilitate tau propagation from entorhinal cort | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms cause the diminishing effect of amyloid on tau spread beyond a c | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines when TMS symptom-specific effects are desirable versus undesirab | open | 0.72 | 0.00 | 2026-04-10 | 0 | | therapeutic-neurostimulation |
| gap-pubmed-20260410- | How can symptom-specific target circuits be systematically identified and valida | open | 0.76 | 0.00 | 2026-04-10 | 0 | | therapeutic-neurostimulation |
| gap-pubmed-20260410- | What neural mechanisms determine why TMS targeting produces symptom-specific rat | open | 0.80 | 0.00 | 2026-04-10 | 0 | | therapeutic-neurostimulation |
| gap-pubmed-20260410- | Does ataxin 3's role in aggresome formation contribute to neurodegeneration or r | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do AT3 mutations that impair aggresome formation also reduce dynein associat | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ataxin 3's deubiquitylating activity mechanistically promote aggresome | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What accounts for the differential sensitivity of biomarker combinations in pred | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do plasma A/T/N biomarkers require APOE ε4 genotype for accurate AD diagnosi | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the variable age of onset (11-29 years) in ATP13A2-related motor | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms explain how ATP13A2 mutations cause overlapping ALS, H | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do sex differences influence microglial lipid metabolism and neurodegenerati | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms explain how DGAT deletion exacerbates neurodegeneratio | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do brain myeloid cells accumulate lipids in endosomes/lysosomes rather than | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the transition from acute to chronic SARM1 activation and sustai | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do T cells mechanistically contribute to motor dysfunction in SARM1-dependen | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms link chronic SARM1 activation to fibroblast chemokine/ | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does SMS1-mediated sphingomyelin synthesis specifically regulate membrane tr | open | 0.73 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-pubmed-20260410- | What molecular mechanism links SMS1 to BACE1 intracellular trafficking regulatio | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do current APOE-targeted therapies focus on microglia/autophagy when oligode | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific molecular mechanisms link APOE4 to cholesterol dysregulation in ol | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms distinguish DNAJB6 from DNAJB1 in suppressing α-synucl | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What alternative methods can generate stable, scalable sources of PSP-specific t | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does 2% sarkosyl-insoluble tau have restricted yield compared to other tau e | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What links UBQLN2-induced ER stress to enhanced TNF-α vulnerability in neurons? | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do dynamic UBQLN2 aggregates mechanistically promote cytoplasmic TDP-43 accu | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the molecular mechanism by which UBQLN2 activates NF-κB through p38 MAPK | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do monomeric BNIP3L mutants fail to induce mitophagy despite being resistant | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What upstream signals trigger proteasomal targeting of BNIP3L specifically durin | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine why dimeric BNIP3L is more susceptible to pr | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the concurrent elevation of both sAPPα and sAPPβ in AD pla | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do CSF and plasma BACE1/sAPP biomarkers show opposite patterns in Alzheimer' | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie DON's effects on dendritic spine density and | open | 0.79 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How does SMS2-mediated sphingomyelin modulation mechanistically protect against | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurometabolism |
| gap-pubmed-20260410- | Why does DON increase BLA-PrL connectivity while simultaneously reducing excitat | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What determines the optimal dosing and timing of GLP-1R agonist intervention in | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does semaglutide's neuroprotective efficacy in PLA2G6-deficient INAD transla | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which semaglutide increases neurop | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What causes the poor positive predictive value (0.33) for Advanced stage AD desp | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does plasma p217+tau fail to distinguish between Initial (A+T-) and Early (A | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the optimal clinical trial design strategies for testing LRRK2 inhibito | resolved | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can LRRK2 inhibitors be effectively translated from genetic PD to sporadic P | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What biomarkers can effectively monitor LRRK2 kinase activity and therapeutic re | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link autophagy-dependent inflammation suppression to A | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does triolein's autophagy inhibition reconcile with autophagy's established | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |